Pub. Date : 2022 Apr 12
PMID : 35413116
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The phase III MIRROS trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia (R/R AML). | RG7388 | MDM2 proto-oncogene | Homo sapiens |